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Dendritic cells not only induce but also modulate
T-cell activation and function. 1,25-dihydroxyvitamin
D3 (1,25(OH)2D3), the prototypic vitamin D receptor
(VDR) ligand, is a hormone that induces dendritic cells
with a tolerogenic phenotype, characterized by decreased
expression of CD40, CD80, and CD86 costimulatory
molecules, low interleukin (IL)-12 and enhanced IL-
10 secretion [1]. We have found that a short treatment
with 1,25(OH)2D3 induces tolerance to fully mismatched
mouse islet allografts that is stable to challenge with
donor-type spleen cells and allows acceptance of donor-
type vascularized heart grafts. This effect is enhanced by
coadministration of mycophenolate mofetil, a selective
inhibitor of T- and B-cell proliferation, that has also ef-
fects similar to 1,25(OH)2D3 on dendritic cells [2]. Graft
acceptance is associated with impaired development of
type 1 CD4+ and CD8+ cells and an increased percent-
age of CD4+ CD25+ regulatory cells expressing CD152
in the spleen and in the draining lymph node. Trans-
fer of CD4+ CD25+ cells from tolerant mice protects
100% of the syngeneic recipients from islet allograft re-
jection. CD4+ CD25+ cells that are able to inhibit the
T-cell response to a pancreatic autoantigen and to signifi-
cantly delay disease transfer by pathogenic CD4+ CD25−
cells are also induced by treatment of adult nonobese
diabetic mice with 1,25-dihydroxy-16,23Z-diene-26,27-
hexafluoro-19-nor vitamin D3 (BXL-922). This treatment
arrests progression of insulitis and Th1 cell infiltration,
and inhibits diabetes development at non-hypercalcemic
doses [3]. The enhancement of CD4+ CD25+ regulatory
T cells able to mediate transplantation tolerance and to
arrest type 1 diabetes development by a short oral treat-
ment with small organic compounds that induce tolero-
genic dendritic cells, like VDR ligands, suggests possible
clinical applications of this approach.
VDR ligands can inhibit not only acute but also chronic
allograft rejection, as documented by inhibition of ad-
ventitial inflammation and intimal hyperplasia in murine
aortic allografts [4]. While the prevention of leukocyte
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infiltration into the adventitia is probably due to the im-
munomodulatory properties of VDR analogues, the inhi-
bition of intimal cell proliferation, both endothelial and
smooth muscle cells, is likely induced by their capacity to
regulate cell growth. Thus, VDR ligands have pleiotropic
immunoregulatory activities that are able to control al-
lograft rejection. Antigen-presenting cells (APCs) and
T cells can be direct targets of the hormone, leading to
the inhibition of pathogenic effector T cells and enhanc-
ing the frequency of T cells with suppressive properties,
largely via induction of tolerogenic dendritic cells [5].
These immunoregulatory activities, coupled with the ab-
sence of major side effects once calcemia is under control,
have been translated into effective immunointervention
in a variety of graft rejection models [6]. This body of
knowledge represents a sound basis to further explore
the immunoregulatory properties of VDR ligands in al-
lograft rejection, and in particular in chronic rejection.
Induction of tolerance to allografts remains an unfulfilled
goal in clinical transplantation, and VDR ligands could
be part of a tolerogenic regimen designed to achieve this
goal.
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